Oncotelic Therapeutics (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003. The committee found no dose-limiting toxicities and recommended advancement to the next planned dose level. The company also revealed plans to expand the study into Europe with additional clinical sites to broaden patient access and support enrollment.
This clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle(TM) nanomedicine platform and the intravenous everolimus formulation Sapu003. According to the company, the publication supports the platform’s scalable manufacturing capabilities, stability, and preclinical antitumor activity while reinforcing the ongoing clinical development program.
The positive safety review is a critical step in the development of Sapu003, which aims to improve the delivery and efficacy of everolimus, a drug used in cancer therapy. The advancement to the next dose level indicates that the formulation is well-tolerated at initial doses, providing a foundation for further dose escalation studies. The planned European expansion is expected to accelerate patient recruitment and provide access to a broader patient population, potentially expediting the drug's development timeline.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing.
The company's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, underpins the Platform and its ongoing joint development work with TechForce Robotics, Oncotelic’s strategic robotics and automation partner. For more information, visit www.oncotelic.com.
This announcement is significant as it demonstrates progress in the clinical development of Sapu003, which could offer a new treatment option for cancer patients. The positive safety review and expansion into Europe highlight the potential of Oncotelic's nanomedicine platform and its commitment to advancing oncology therapies.
